Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-β in rodents and nonhuman primates

Human Gene Therapy

Volumn 21, Issue 4, 2010, Pages 451-462

  Jenks, Nathan ^a   Myers, Rae ^a   Greiner, Suzanne M ^a   Thompson, Jill ^a   Mader, Emily K ^a   Greenslade, Andrew ^a   Griesmann, Guy E ^a   Federspiel, Mark J ^a   Rakela, Jorge ^b   Borad, Mitesh J ^b   Vile, Richard G ^a   Barber, Glen N ^c   Meier, Thomas R ^a   Blanco, Michael C ^a   Carlson, Stephanie K ^a   Russell, Stephen J ^a   Peng, Kah Whye ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BETA INTERFERON; INTERLEUKIN 6; ONCOLYTIC VIRUS; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; BEHAVIOR; BLOOD EXAMINATION; BODY WEIGHT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD TILTING; LIVER; LIVER CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PARALYSIS; PHIMOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RHESUS MONKEY; SEIZURE; THROMBOCYTE COUNT; TISSUE CULTURE; TREMOR; VESICULAR STOMATITIS VIRUS; VIRUS INFECTIVITY; VIRUS RECOMBINANT; WEIGHT REDUCTION; XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CERCOPITHECUS AETHIOPS; DRUG ADMINISTRATION ROUTES; FEMALE; GENETIC VECTORS; HUMANS; INTERFERON-BETA; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MACACA MULATTA; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; VERO CELLS; VESICULAR STOMATITIS INDIANA VIRUS;

ANIMALIA; MACACA; MACACA MULATTA; PRIMATES; RATTUS; RATTUS NORVEGICUS; RODENTIA; VESICULAR STOMATITIS VIRUS;

EID: 77950957568     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.111     Document Type: Article

References (35)

1. Ahmed, M., Marino, T.R., Puckett, S., Kock, N.D., and Lyles, D.S. (2008). Immune response in the absence of neurovirulence in mice infected with M protein mutant vesicular stomatitis virus. J. Virol. 82, 9273-9277.
2. Altomonte, J., Braren, R., Schulz, S., Marozin, S., Rummeny, E.J., Schmid, R.M., and Ebert, O. (2008). Synergistic antitumor effects of transarterial viroembolization for multifocal hepato-cellular carcinoma in rats. Hepatology 48, 1864-1873.
3. Barber, G.N. (2004). Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 17, 516-527.
4. Barber, G.N. (2005). VSV-tumor selective replication and protein translation. Oncogene 24, 7710-7719.
5. Bi, Z., Barna, M., Komatsu, T., and Reiss, C.S. (1995). Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J. Virol. 69, 6466-6472.
6. Blum, H.E. (2005). Hepatocellular carcinoma: Therapy and prevention. World J. Gastroenterol. 11, 7391-7400.
7. Clarke, D.K., Cooper, D., Egan, M.A., Hendry, R.M., Parks, C.L., and Udem, S.A. (2006). Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin. Immunopathol. 28, 239-253.
8. Cooper, D., Wright, K.J., Calderon, P.C., Guo, M., Nasar, F., Johnson, J.E., Coleman, J.W., Lee, M., Kotash, C., Yurgelonis, I., Natuk, R.J., Hendry, R.M., Udem, S.A., and Clarke, D.K. (2008). Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neuro-virulence and enhances immunogenicity in mice. J. Virol. 82, 207-219.
9. Damdinsuren, B., Nagano, H., Wada, H., Kondo, M., Ota, H., Nakamura, M., Noda, T., Natsag, J., Yamamoto, H., Doki, Y., Umeshita, K., Dono, K., Nakamori, S., Sakon, M., and Monden, M. (2007). Stronger growth-inhibitory effect of in-terferon (IFN)-b compared with IFN-a is mediated by IFN signaling pathway in hepatocellular carcinoma cells. Int. J. Oncol. 30, 201-208.
10. Ebert, O., Shinozaki, K., Huang, T.G., Savontaus, M.J., Garcia-Sastre, A., and Woo, S.L. (2003). Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 63, 3605-3611.
11. Ebert, O., Shinozaki, K., Kournioti, C., Park, M.S., Garcia-Sastre, A., and Woo, S.L. (2004). Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res. 64, 3265-3270.
12. d system. J. Virol. 65, 4950-4958.
13. Garcia-Sastre, A., and Biron, C.A. (2006). Type 1 interferons and the virus-host relationship: A lesson in detente. Science 312, 879-882.
14. Goel, A., Carlson, S.K., Classic, K.L., Greiner, S., Naik, S., Power, A.T., Bell, J.C., and Russell, S.J. (2007). Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(D51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 110, 2342-2350.
15. Hadac, E.M., Peng, K.W., Nakamura, T., and Russell, S.J. (2004). Reengineering paramyxovirus tropism. Virology 329, 217-225.
16. Johnson, J.E., Nasar, F., Coleman, J.W., Price, R.E., Javadian, A., Draper, K., Lee, M., Reilly, P.A., Clarke, D.K., Hendry, R.M., and Udem, S.A. (2007). Neurovirulence properties of recom-binant vesicular stomatitis virus vectors in non-human primates. Virology 360, 36-49.
17. Kamiyama, T., Nakanishi, K., Yokoo, H., Kamachi, H., Tahara, M., Suzuki, T., Shimamura, T., Furukawa, H., Matsushita, M., and Todo, S. (2009). Recurrence patterns after hepatectomy of hepatocellular carcinoma: Implication of Milan criteria utilization. Ann. Surg. Oncol. 16, 1560-1571.
18. Kopecky, S.A., Willingham, M.C., and Lyles, D.S. (2001). Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J. Virol. 75, 12169-12181.
19. Kottke, T., Diaz, R.M., Kaluza, K., Pulido, J., Galivo, F., Wongthida, P., Thompson, J., Willmon, C., Barber, G.N., Chester, J., Selby, P., Strome, S., Harrington, K., Melcher, A., and Vile, R.G. (2008). Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol. Ther. 16, 1910-1918.
20. Lichty, B.D., Power, A.T., Stojdl, D.F., and Bell, J.C. (2004). Vesicular stomatitis virus: Re-inventing the bullet. Trends Mol. Med. 10, 210-216.
21. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., De Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T.F., Galle, P.R., Seitz, J.F., Borbath, I., Haussinger, D., Gian-naris, T., Shan, M., Moscovici, M., Voliotis, D., and Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390.
22. DM51) on multifocal and invasive gliomas. J. Natl. Cancer Inst. 98, 1546-1557.
23. Murata, M., Nabeshima, S., Kikuchi, K., Yamaji, K., Furusyo, N., and Hayashi, J. (2006). A comparison of the antitumor effects of interferon-a and b on human hepatocellular carcinoma cell lines. Cytokine 33, 121-128.
24. Nguyen, T.L., Abdelbary, H., Arguello, M., Breitbach, C., Leveille, S., Diallo, J.S., Yasmeen, A., Bismar, T.A., Kirn, D., Falls, T., Snoulten, V.E., Vanderhyden, B.C., Werier, J., Atkins, H., Vaha-Koskela, M.J., Stojdl, D.F., Bell, J.C., and Hiscott, J. (2008). Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. U.S.A. 105, 14981-14986.
25. Novella, I.S., Ball, L.A., and Wertz, G.W. (2004). Fitness analyses of vesicular stomatitis strains with rearranged genomes reveal replicative disadvantages. J. Virol. 78, 9837-9841.
26. Obuchi, M., Fernandez, M., and Barber, G.N. (2003). Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77, 8843-8856.
27. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108.
28. Qiao, J., Wang, H., Kottke, T., Diaz, R.M., Willmon, C., Hudacek, A., Thompson, J., Parato, K., Bell, J., Naik, J., Chester, J., Selby, P., Harrington, K., Melcher, A., and Vile, R.G. (2008). Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther.15, 604-616
29. Russell, S.J., and Peng, K.W. (2007). Viruses as anticancer drugs. Trends Pharmacol. Sci. 28, 326-333.
30. Shin, E.J., Wanna, G.B., Choi, B., Aguila, D., III, Ebert, O., Genden, E.M., and Woo, S.L. (2007). Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in mu-rine squamous cell carcinoma. Laryngoscope 117, 210-214.
31. Stojdl, D.F., Lichty, B.D., Tenoever, B.R., Paterson, J.M., Power, A.T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., Brown, E.G., Durbin, R.K., Durbin, J.E., Hiscott, J., and Bell, J.C. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263-275.
32. Ueshima, K., Kudo, M., Nagai, T., Tatsumi, C., Ueda, T., Takahashi, S., Hatanaka, K., Kitai, S., Ishikawa, E., Inoue, T., Hagiwara, S., Minami, Y., and Chung, H. (2008). Combination therapy with S-1 and pegylated interferon a for advanced hepatocellular carcinoma. Oncology 75(Suppl. 1), 106-113.
33. Verslype, C., Van Cutsem, E., Dicato, M., Arber, N., Berlin, J.D., Cunningham, D., DeGramont, A., Diaz-Rubio, E., Ducreux, M., Gruenberger, T., Haller, D., Haustermans, K., Hoff, P., Kerr, D., Labianca, R., Moore, M., Nordlinger, B., Ohtsu, A., Rougier, P., Scheithauer, W., Schmoll, H.J., Sobrero, A., Tabernero, J., and van de Velde, C. (2009). The management of hepatocellular carcinoma: Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann. Oncol. 20(Suppl. 7), vii1-vii6.
34. Villinger, F., Brar, S.S., Mayne, A., Chikkala, N., and Ansari, A.A. (1995). Comparative sequence analysis of cytokine genes from human and nonhuman primates. J. Immunol. 155, 3946-3954.
35. Wu, L., Huang, T.G., Meseck, M., Altomonte, J., Ebert, O., Shinozaki, K., Garcia-Sastre, A., Fallon, J., Mandeli, J., and Woo, S.L. (2008). rVSV(MD51)-M3 is an effective and safe on-colytic virus for cancer therapy. Hum. Gene Ther. 19, 635-647.